THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)

I.B Mcinnes,G Ligozio,D Van Der Heijde,H Richards,C Ritchlin,A.B Gottlieb,L Pricop,A Kavanaugh,P Rahman,B Kirkham,S Mpofu,P Mease,P.G Conaghan,R Landewé

doi:10.1136/annrheumdis-2015-eular.2265

THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)

I.B Mcinnes, G Ligozio + Show 12 more

https://doi.org/10.1136/annrheumdis-2015-eular.2265

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2015
Citations: 1

Affiliation: Tris Pharma (United States), Novartis (United States), Novartis (Switzerland), University of Rochester Medical Center, University of California, San Diego, Memorial University of Newfoundland, St Thomas' Hospital, Seattle University, Swedish Medical Center, University of Washington, University of Amsterdam

#Symptoms Of Psoriatic Arthritis #Symptoms Of Active Psoriatic Arthritis + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundSecukinumab, a human anti–IL-17A monoclonal antibody, has demonstrated efficacy with an intravenous loading and subcutaneous (s.c.) maintenance regimen in psoriatic arthritis (PsA) (FUTURE 1; NCT01392326).ObjectivesTo evaluate the efficacy and safety...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.